The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 31-32 , July 2010

Peanut oral immunotherapy is not ready for clinical use

  • Ananth Thyagarajan, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Pooja Varshney, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Stacie M. Jones, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Ark
    • ,
  • Scott Sicherer, MD

      Affiliations

    • Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY
    • ,
  • Robert Wood, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, the Johns Hopkins University School of Medicine, Baltimore, Md
    • ,
  • Brian P. Vickery, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Hugh Sampson, MD

      Affiliations

    • Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY
    • ,
  • A. Wesley Burks, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: A. Wesley Burks, MD, Division of Allergy and Immunology, Duke University Medical Center, Box 2898, Durham, NC 27710.

Received 20 April 2010 ,Revised 7 May 2010 ,Accepted 10 May 2010.

References 

  1. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–145
  2. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;124:1549–1555
  3. Ben-Shoshan M, Kagan RS, Alizadehfar R, Joseph L, Turnbull E, St Pierre Y, et al. Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal. J Allergy Clin Immunol. 2009;123:783–788
  4. Mullins RJ, Dear KB, Tang ML. Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. J Allergy Clin Immunol. 2009;123:689–693
  5. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11 year follow-up. J Allergy Clin Immunol. 2010;125:1322–1326
  6. Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med. 2009;60:261–277
  7. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292–300e1-97
  8. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122:1154–1160
  9. Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119:199–205
  10. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008;121:343–347
  11. Narisety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. J Allergy Clin Immunol. 2009;124:610–612
  12. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, Lopes de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126:83–91
  13. Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics. 1998;102:e6
  14. Clark AT, Ewan PW. Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center. J Allergy Clin Immunol. 2008;122:286–289
  15. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124:286–291
  16. Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124:1351–1352
  17. Scurlock AM, Burks AW, Jones SM. Oral immunotherapy for food allergy. Curr Allergy Asthma Rep. 2009;9:186–193
  18. Bird A, Daly D, Burks W, Hourihane JOB, DunnGalvin A. Impact of oral food-specific immunotherapy (OIT) on health related quality of life (HRQL) of children and parents during build up of tolerance. J Allergy Clin Immunol. 2010;125:AB22
  19. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009;64:1218–1220
  20. Rolinck-Werninghaus C, Staden U, Mehl A, Hamelmann E, Beyer K, Niggemann B. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy?. Allergy. 2005;60:1320–1322

 Disclosure of potential conflict of interest: S. M. Jones has received research support from the National Peanut Board, the National Institutes of Health (NIAID), and DYAX Corp and is on the Medical Advisory Board for the Food Allergy and Anaphylaxis Network. S. Sicherer is a consultant for the Food Allergy Initiative and has received research support from the National Institutes of Health (NIAID), the Food Allergy and Anaphylaxis Network, and the Food Allergy Initiative. R. Wood has received research support from the National Institutes of Health and is on the Medical Advisory Board for the Food Allergy and Anaphylaxis Network. B. P. Vickery has received research support from the Thrasher Research Fund and the National Institutes of Health (NIAID). H. Sampson is a consultant for Allertein, LLC; has received research support from the Food Allergy Initiative and the National Institutes of Health (NIAID); is a consultant and scientific advisor for the Food Allergy Initiative; and is 45% owner of Herbal Springs, LLC. A. W. Burks is a consultant for ActoGeniX NV, Intelliject, McNeil Nutritionals, and Novartis; is a minority stockholder in Allertein and MastCell, Inc; is on the Advisory Board for Dannon Co Probiotics; is on the expert panel for Nutricia; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Wallace Research Foundation; has served as an expert witness on the topic of food allergy; is on the Medical Board of Directors for the Food Allergy and Anaphylaxis Network; is a Dermatological Allergy Committee Member for the American College of Allergy, Asthma, and Immunology; is a Study Section Member for the National Institutes of Health (HAI); and is on the Reviewer Board for the Journal of Allergy and Clinical Immunology and the US Food and Drug Administration. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(10)00813-4

doi: 10.1016/j.jaci.2010.05.012

The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 31-32 , July 2010

Article Tools